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AbstrACt 
Objective Smoking is the main modiiable cancer risk 
factor. The objective of this study was to examine the 
impact of smoking on health system costs among newly 
diagnosed adult patients with cancer. Speciically, costs 
of patients with cancer who were current smokers were 
compared with those of non-smokers from a publicly 
funded health system perspective.
Methods This population-based cohort study of patients 
with cancer used administrative databases to identify 
smokers and non-smokers (1 April 2014–31 March 2016) 
and their healthcare costs in the 12–24 months following 
a cancer diagnosis. The health services included were 
hospitalisations, emergency room visits, drugs, home 
care services and physician services (from the time of 
diagnosis onwards). The difference in cost (ie, incremental 
cost) between patients with cancer who were smokers 
and those who were non-smokers was estimated using 
a generalised linear model (with log link and gamma 
distribution), and adjusted for age, sex, neighbourhood 
income, rurality, cancer site, cancer stage, geographical 
region and comorbidities.
results This study identiied 3606 smokers and 14 911 
non-smokers. Smokers were signiicantly younger (61 vs 
65 years), more likely to be male (53%), lived in poorer 
neighbourhoods, had more advanced cancer stage,and 
were more likely to die within 1 year of diagnosis, 
compared with non-smokers. The regression model 
revealed that, on average, smokers had signiicantly higher 
monthly healthcare costs ($5091) than non-smokers 
($4847), p<0.05.
Conclusions Smoking status has a signiicant impact 
on healthcare costs among patients with cancer. On 
average, smokers incurred higher healthcare costs than 
non-smokers. These indings provide a further rationale 
for efforts to introduce evidence-based smoking cessation 
programmes as a standard of care for patients with cancer 
as they have the potential not only to improve patients’ 
outcomes but also to reduce the economic burden of 
smoking on the healthcare system.
IntrOduCtIOn
Cancer care is a substantial component of 
healthcare expenditures of developed coun-
tries.1–3 In Canada, the economic burden 
of cancer was estimated to be $7.5 billion in 
2012.4 It is well recognised that smoking is the 
main modifiable risk factor for cancer,5 and 
it is estimated that it contributes to approxi-
mately 30% of all cancer deaths.6 7 Smoking 
can also harm directly or indirectly almost 
every organ of the body and is responsible 
for a number of other chronic diseases that 
contribute to higher healthcare costs.5 8–11 
Quitting smoking after a diagnosis of cancer 
has been associated with improved general 
health, better quality of life, reduced toxicity, 
greater response to treatment (such as radi-
ation therapy) and decreased risk of disease 
recurrence and second primary cancers.12–18 
Nevertheless, patients with cancer are just as 
likely to smoke as the general public, with the 
strengths and limitations of this study
 Ź Findings from this study represent one piece of evi-
dence in support of the integration of smoking ces-
sation programmes into cancer care treatment plans 
as a standard of practice.
 Ź This study adds to the literature by providing up-
to-date and precise healthcare cost estimates of 
smoking using existing administrative person-level 
costing approaches.
 Ź A limitation of this study is that it excludes a subset 
of relevant variables that may have had an inluence 
on health outcomes and cost due to the nature of 
the study design (eg, type of tumour, amount and 
duration of smoking).
 Ź This study focused on the cost incurred to the pub-
lic healthcare payer and, therefore, indirect costs 
were not considered but could be explored in future 
research.
 Ź The indings from this study should motivate poli-
cy makers to design, implement and fund smoking 
cessation programmes, which have the potential not 
only to improve patients’ treatment outcomes but 
also to reduce the economic burden of smoking on 
the healthcare system.
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smoking rate being approximately 20%.19 Furthermore, 
smoking cessation programmes are rare in oncology 
settings.12 13 20
Although the impact of smoking on healthcare costs 
has been examined in the general population, there is 
very little information on the impact of smoking on the 
cost of cancer care in patients who are smokers compared 
with those who are not.
The study objective was to compare the health system 
costs of patients with cancer who were current smokers 
with those of non-smokers between 2014 and 2016, from 
the perspective of a public healthcare payer, using admin-
istrative databases in Ontario, Canada. We hypothesised 
that smoking would be associated with higher overall 
health system costs as a result of the need to manage 
more frequent and severe toxicities of treatment, more 
frequent disease recurrence and more non-cancer-related 
morbidities. Understanding the cost burden of smokers 
with cancer may help drive policy change by providing an 
economic argument for investing in cessation resources 
and programmes for patients with cancer who smoke.
MAterIAls And MethOds
This study was a secondary data analysis using existing 
administrative databases at Cancer Care Ontario (CCO) 
and the Institute for Clinical Evaluative Sciences (ICES), 
both located in Toronto, Ontario, Canada. 
study population and setting
The study population consisted of newly diagnosed adult 
patients with cancer, aged ≥18 years, who received ambu-
latory care from one of the 14 Regional Cancer Centres 
(RCCs) in Ontario, Canada, between 1 April 2014 and 
31 March 2015. The Ontario Cancer Registry (OCR) 
was used to identify our study population. We excluded 
patients with (1) an invalid health card (ie, who were not 
eligible for public healthcare insurance); (2) an invalid 
death date (ie, where death date was on or before the 
date of diagnosis); (3) missing data on smoking status; 
(4) a cancer stage of zero; (5) missing data on neigh-
bourhood-level income, geographical location or rurality 
of residence; (6) lost healthcare coverage during the 
follow-up time; or (7) multiple cancers. Each patient 
was followed until death or the end of the observation 
period (31 March 2016), whichever came first. Online 
S1 appendix provides a flow diagram of the number of 
patients excluded from the analysis.
study population subgroups (smokers and non-smokers)
The study population of patients with cancer was 
divided into those who were identified as smokers and 
non-smokers. Patients with cancer who were either 
currently smoking at the time of diagnosis or who had 
smoked in the previous 6 months of their first ambula-
tory care visit were identified as smokers, whereas all others 
were identified as non-smokers. Information on smoking 
status was obtained from the CCO Smoking Cessation Dataset 
(CCOSCD), which is part of the Activity Level Reporting 
(ALR) database housed at CCO. The CCOSCD collects 
information on the self-reported smoking status of newly 
diagnosed ambulatory patients with cancer, whether the 
current smoker has been advised to quit, and whether the 
patient has been referred for smoking cessation coun-
selling and/or pharmacotherapy.21 Each RCC submits 
the data on these metrics on a monthly basis to CCO as 
part of CCO’s Smoking Cessation Programme. Online S2 
appendix describes the data elements in the data set and 
their definitions.
data sources and variables
A number of databases were used to obtain healthcare 
utilisation data: the ALR database, the New Drug Funding 
Programme database, the Ontario Drug Benefit claims 
database, the Discharge Abstract Database obtained 
from the Canadian Institute for Health Information 
(CIHI), the National Ambulatory Care Reporting System 
obtained from CIHI, the Ontario Health Insurance 
Programme claims database, the Home Care Database, 
the Continuing Care Reporting System and the National 
Rehabilitation Reporting System. Table 1 provides a brief 
description of each database.
healthcare costs
The outcome of interest for the study was total and disag-
gregated healthcare costs from the perspective of the 
Ontario Ministry of Health and Long-Term Care from 
the time of diagnosis. Patients in Ontario receive publicly 
funded healthcare, which covers costs for health services 
(eg, hospitalisation) including the costs of most drugs 
for patients over the age of 65 years or who are on social 
assistance. Healthcare costs included costs associated with 
hospitalisations, same-day surgeries, emergency room 
(ER) visits, outpatient prescription drugs, rehabilitation, 
complex continuing care, home care services, physi-
cian services, and laboratory and diagnostic tests. Cost 
estimates were derived using an existing costing algo-
rithm at ICES. For example, hospitalisations and ER visit 
costs were estimated by multiplying a resource intensity 
weight (measure of utilisation) with an average cost per 
hospital stay or ER visit (unit cost).22 Physician visit costs 
were obtained from the Ontario Schedule of Benefits for 
Physician Services.23 Additional details on the methods 
to estimate cost can be found elsewhere.4 22 24 Costs were 
adjusted to 2016 Canadian dollars ($C) using the health 
component of the Consumer Price Index in healthcare 
category ($C1=approximately US$0.78).25
Other variables
Due to potential differences between smokers and 
non-smokers, we controlled for patient characteristics 
by adjusting for a number of variables such as age at 
diagnosis, sex, cancer site, cancer stage (where avail-
able), geographical location of residence (ie, rurality 
and Local Health Integration Network (LHIN)), neigh-
bourhood income quintile and comorbidity (measured 
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by the Adjusted Clinical Groups or ACG), all of which 
were obtained from the previously mentioned data-
bases. In Ontario, publicly funded healthcare services 
are administered on a regional basis by the LHINs, 
which serve as the regional health authority. Each of 
the 14 LHINs is responsible for a distinct geographical 
location.26 The ACG system is a patient case-mix adjust-
ment system used to measure health status by grouping 
diagnoses into clinical groups. The goal of this system is 
to assign each patient a single value, which represents 
the patient’s comorbidity through his/her expected or 
actual use of health services, where a higher number 
refers to a greater number of comorbidities (0–4, 5–6, 
7–9 and 10+).27 In this study, this value was assigned at 
the time of the cancer diagnosis. Cancer sites or group-
ings were reported on as follows: bladder; bronchus 
and lung; breast; colorectal; corpus uteri; head and 
neck; prostate; melanoma; and ‘other’. Other included 
cancers of the anus and anal canal, brain, oesophagus, 
haematopoietic system, liver, ovary, pancreas, renal, 
stomach, testis and thyroid. The four most common 
types of cancer were lung, breast, colorectal and pros-
tate cancer. The extent of cancer was reported in one of 
three groups: stage 1–2; stage 3–4; and unknown stage. 
Cancer stage data in Ontario were available predomi-
nantly for the four most common types of cancer (eg, 
lung, breast, prostate and colorectal); therefore, it was 
necessary to create a separate category for unknown 
cancer stage.
AnAlysIs
The raw costs for non-smokers and smokers were reported 
descriptively. To adjust for different follow-up times, 
as some patients (particularly smokers) have a greater 
chance of dying than non-smokers, we estimated person-
month costs.28
The output of the economic analysis was the incre-
mental cost (reported in 2016 CAD) between patients 
with cancer who smoked and those who did not. We anal-
ysed our dependent variable (monthly healthcare costs) 
using regression models to estimate the difference in 
expected healthcare cost between the two groups using 
recycled predictive methods,28–30 as described in the 
following equation:
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, where cost
i
 represents a monthly cost of 
patient I; β
x
 refers to a coefficient estimate of each variable, 
X, such as smoking status, age and sex; and ε represents the 
error term. The smoking status variable was the primary 
independent variable, and the regression model was 
adjusted for potential confounding variables, such as age, 
sex, income, rurality, cancer stage, cancer site, geograph-
ical region (LHIN) and comorbidity. To accommodate for 
the skewness of cost data, a generalised linear model with 
log link and gamma family was used to estimate the incre-
mental cost between smokers and non-smokers.28 31 We also 
conducted a modified Park test to ensure that our selected 
model was the best fit.28 31 Collinearity was also explored 
using a variance inflation factor, and we found no evidence 
of collinearity. Online S3 appendix reports a completed 
Strengthening the Reporting of Observational Studies in 
Epidemiology statement, a checklist of items that should be 
included in reports of cohort studies.
Patient and public involvement
There was no involvement of patients during the study 
period but there are knowledge translation activities with 
various knowledge users.
results
There were 3606 smokers and 14 911 non-smokers in 
our study cohort (see table 2). Patients with cancer who 
smoked were significantly younger (61 vs 65 years), more 
Table 1 Administrative databases used in the analysis
Database Description
OCR The Ontario Cancer Registry is the largest population-
based cancer registry in Canada. The OCR contains 
over 300 ields, including primary site of cancer, 
county of residence at diagnosis and health insurance 
number.
ALR The Ontario Activity Level Reporting provides a set of 
data elements from selected Ontario Cancer Centres 
that cannot be obtained from other providers. This 
information is used to support management decision-
making process.
NDFP The New Drug Funding Programme data are used 
for reimbursement decisions and to support cancer 
system planning for systemic therapy. To be eligible 
for reimbursement through the NDFP, hospitals must 
submit eligibility/enrolment data and treatment data 
in compliance with monthly billing deadlines. For 
treatment reimbursement, each patient must be 
enrolled in the NDFP by providing eligibility/enrolment 
data that include patient-speciic demographic 
information and answers to a series of medical 
questions.
ODB The Ontario Drug Beneit Formulary lists prescription 
drugs that are covered for patients over 65 years and 
selected other groups (eg, those that require income 
supports).
CIHI DAD Hospitalisation and comorbidity data are in the 
Discharge Abstract Database from the Canadian 
Institute for Health Information.
CIHI 
NACRS
Emergency room visits and same-day surgery data 
were obtained from the National Ambulatory Care 
Reporting System.
OHIP Ontario Health Insurance Programme reports 
outpatient physician visits based on fee-for-service 
claims.
HCD Home Care Database captures all home care services 
in Ontario.
CCRS The Continuing Care Reporting System reports 
utilisation of continuing care.
NRS National Rehabilitation Reporting System captures 
rehabilitation utilisation.
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likely to be male (53% vs 45%), live in lower income 
neighbourhoods (25% of smokers compared with 16% of 
non-smokers were in the lowest income quintile) and more 
likely to live in rural areas (18% vs 15%) compared with 
patients with cancer who were non-smokers. Cancer stage 
data were available for approximately 70% of patients over 
the study period. Of those with available cancer stage data, 
smokers were more likely to have advanced cancer stages 
than non-smokers. Almost 40% of smokers were in stage 
3–4 compared with approximately 27% of non-smokers. 
Roughly 25% of smokers died within 1 year of diagnosis 
compared with 15% of non-smokers who died over the 
same follow-up period. Approximately 30% of smokers 
were in the lowest comorbidity level (0–4) compared 
with 24% of non-smokers. Only 19% of smokers were 
in the highest comorbidity level (10+) compared with 
23% of non-smokers. Among all cancer types studied, 
lung cancer was the most common type of cancer among 
smokers followed by breast cancer. For non-smokers, the 
most common cancer type was breast cancer followed by 
prostate cancer and lung cancer (table 2); all three were 
identified as common types of cancer.
Online S4 appendix reports the unadjusted monthly 
healthcare costs between the study groups. Generally, 
smokers incurred higher healthcare costs than non-smokers 
for hospitalisations, physician services, ER visits, home care 
services and complex continuing care. Focusing on specific 
types of healthcare costs, smokers had approximately 30% 
higher hospitalisation costs, 43% higher ER visit costs, 23% 
higher physician visit costs and 30% higher home care 
costs than non-smokers. Overall, total monthly healthcare 
costs were higher among smokers ($5649 ± $7169) than 
non-smokers ($4704 ± $6737).
From the adjusted regression model (controlling for age, 
sex, income, rurality, stage, disease site, geographical region 
and comorbidity), on average, smokers had significantly 
higher monthly healthcare costs ($5091) than non-smokers 
($4847). Smokers incurred $244 (±113; 95% CI $242, $245 
and IQR $145, $328) more in healthcare cost per month, or 
$2928 more per year than non-smokers, p=0.0047.
dIsCussIOn
Understanding the impact of smoking on the healthcare 
costs of patients with cancer may strengthen the rationale 
for decision makers to further invest in smoking cessation 
programmes. It is generally understood that smoking can 
lead to worse clinical outcomes, but there is a paucity of 
literature on the impact of smoking on healthcare costs 
among patients with cancer. The findings from this anal-
ysis are aligned with the limited available literature. Specif-
ically, we found that patients with cancer who were smokers 
were younger and more commonly males compared with 
patients with cancer who were not smokers, which is in 
line with the literature.10 32 Additionally, smokers had, 
on average, almost 20% higher total monthly health-
care costs than non-smokers. When focusing mainly on 
hospitalisations, the incremental cost due to smoking was 
approximately 30% higher than non-smokers, in contrast 
to an increase of up to 50% in incremental hospitalisa-
tion costs among smokers reported in the literature.9 33 
Our findings suggest that patients with cancer who are 
smokers are responsible for a greater economic burden 
than non-smokers.
Table 2 Demographic characteristics of study population 
between smokers and non-smokers
Variable* Non-smokers Smokers
n 14 911 3606
Mean age in years (SD) 65.1 (13.6) 60.6 (12.1)
Male 6681 (44.8%) 1907 (52.9%)
Age groups in years, n (%)
  18–44 1116 (7.5%) 310 (8.6%)
  45–54 1973 (13.2%) 661 (18.3%)
  55–64 3443 (23.1%) 1217 (33.7%)
  65–74 4525 (30.3%) 1035 (28.7%)
  75+ 3854 (25.8%) 383 (10.6%)
Income quintile, n (%)
  1 (lowest) 2387 (16.0%) 887 (24.5%)
  2 2597 (17.4%) 818 (22.7%)
  3 3065 (20.6%) 691 (19.2%)
  4 3351 (22.5%) 649 (18.0%)
  5 (highest) 3511 (23.5%) 561 (15.6%)
Living in rural areas, n (%) 2267 (15.2%) 662 (18.4%)
Death within 1 year, n (%) 2211 (14.8%) 850 (23.6%)
Mean time from diagnosis to 
death (SD)
255.2 days (163.3) 236.8 days (159.6)
Comorbidity (ACG), n (%)
  0–4 3589 (24.1%) 1092 (30.3%)
  5–6 3295 (22.1%) 838 (23.2%)
  7–9 4533 (30.4%) 985 (27.3%)
  10+ 3494 (23.4%) 691 (19.2%)
Cancer stage, n (%)
  1–2 6378 (42.8%) 1289 (35.7%)
  3–4 3958 (26.5%) 1392 (38.6%)
  Unknown 4575 (30.7%) 925 (25.7%)
Cancer types, n (%)
  Lung 1673 (11.2%) 1017 (28.2%)
  Breast 3088 (20.7%) 497 (13.8%)
  Head and neck 614 (4.1%) 292 (8.1%)
  Prostate 1694 (11.4%) 290 (8.0%)
  Colorectal 1460 (9.8%) 268 (7.4%)
  Melanoma 563 (3.8%) 81 (2.2%)
  Corpus uteri 701 (4.7%) 64 (1.8%)
  Bladder 196 (1.3%) 43 (1.2%)
  Other 4922 (33.0%) 1054 (29.3%)
*The two groups were signiicantly different across all variables 
(p<0.05).
ACG, Adjusted Clinical Groups; n, sample size.
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Evidence on the importance of smoking cessation for 
patients with cancer has strengthened in recent years. 
Several cancer care institutions in the USA have emerged 
as leaders in this field by incorporating smoking cessa-
tion programmes into practice.34 Ontario is the first 
jurisdiction in North America to implement a systematic 
smoking cessation programme in all of its RCCs. Under 
the leadership of CCO, the provincial agency responsible 
for improving the quality of cancer services in Ontario, a 
smoking cessation programme provides support for new 
ambulatory patients with cancer by screening patients 
for tobacco use, advising on the benefits of quitting and 
offering referrals to smoking cessation resources. Under-
standing the impact of smoking on the healthcare costs 
incurred by patients with cancer may further strengthen 
the rationale for the programme and encourage policy 
makers (eg, public healthcare payer) to invest in smoking 
cessation programmes. The findings from this study may 
also be beneficial to other cancer agencies and not-for-
profit organisations (eg, American Cancer Society, World-
wide Cancer Research and Canadian Partnership Against 
Cancer) engaged in developing smoking cessation poli-
cies and implementing smoking cessation programmes. In 
addition, this study may help to inform the general public 
about the burden of smoking among patients with cancer 
and motivate hospital and health system administrators 
about the incremental economic impact of failing to help 
patients with cancer quit smoking. The findings from this 
study represent a further piece of evidence in support 
of the integration of smoking cessation programmes 
into cancer care treatment plans (in settings similar to 
the study setting) and will hopefully stimulate further 
research into the optimal implementation of smoking 
cessation programmes in order to improve cancer care 
outcomes and reduce morbidity, mortality and cost.
This study has strengths and limitations, which should 
be highlighted. The medical literature has called for 
more up-to-date and precise healthcare cost estimates of 
smoking.9 35 Existing Canadian literature has used cost 
estimates for smokers from the 1990s and/or employed 
high-level costing approaches, instead of using patient-level 
cost estimates. These prior estimates might not accurately 
reflect the true healthcare cost difference between smokers 
and non-smokers.9 35–37 This study represents a first step in 
systematically collecting these data and linking them to data 
on system-level resources. Furthermore, using existing data 
from administration databases, we were able to conduct the 
analysis with adjustment of potential confounders to increase 
the validity of the findings.
In terms of limitations, data on smoking status were 
limited to one assessment during the initial consulta-
tion period (28 days) for new ambulatory patients with 
cancer. Therefore, it is possible that patients may have 
changed their smoking status after their cancer diagnosis 
but data on change in smoking status were not captured. 
Our analysis followed the intent-to-treat principle and was 
applied to both study groups (ie, smokers at the time of 
diagnosis or who had quit in the last 6 months remained 
smokers throughout the analysis and vice versa). If some 
‘smokers’ quit smoking, their medical outcomes or toler-
ance to treatment may have been better than that of 
persistent smokers (presumably with less resource util-
isation and less cost). Consequently, this analysis may 
have provided a lower bound of the incremental cost. 
Individuals who had quit prior to 6 months would likely 
still have more health complications and resource utili-
sation than life-long non-smokers. Classification of these 
patients as non-smokers may again lead to the possibility 
of an underestimation of the difference in cost between 
smokers and non-smokers. The data available on smoking 
status limited our ability to analyse former smokers and 
recent quitters as separate groups.
Our analysis was also limited by the available follow-up 
data. As the follow-up period was relatively short, it is 
possible that significant differences might be observed 
with a longer period of follow-up. It is also possible that, 
given the nature of the study design, relevant variables 
were not collected. For example, cancer stage data were 
available for the common types of cancer (ie, lung, breast, 
colorectal and prostate cancer), but not for some other 
tumour types, such as head and neck cancer. In addition 
to the common cancer types, our study included other 
tumour types (eg, brain, liver) but their smaller numbers 
did not allow us to examine them separately. This could be 
a future area of research. Patients with multiple cancers 
were excluded from the study to distinguish the impact of 
smoking on a single tumour type. In addition, there were 
no data available on the amount or duration of smoking, 
which would likely have an influence on health outcomes 
and cost. Smoking has been shown to increase both direct 
and indirect costs.9 36 37 However, because our study used 
administrative data, indirect costs were not explored. 
Future clinical trials could consider prospectively docu-
menting the specific clinical and financial benefits of 
smoking cessation as part of clinical care to evaluate the 
smoking cessation programmes. Finally, the cost to imple-
ment a smoking cessation programme was not included 
in this analysis and may cancel out some of the economic 
benefits of helping smokers to stop smoking.
In conclusion, the smoking status of patient with 
cancer has a significant impact on health system costs. On 
average, smokers incurred higher healthcare costs than 
non-smokers. These findings provide an additional reason 
for the introduction of evidence-based smoking cessation 
programmes for patients with cancer. The findings from 
this study should motivate policy makers to fund, design 
and implement smoking cessation programmes, which 
have the potential not only to improve patients’ treat-
ment outcomes but also to reduce the economic burden 
of smoking on the healthcare system.
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